It is expected that the gut microbiota composition is associated with antitumor efficacy in patients with metastatic melanoma treated with anti-CTLA-4 and anti-programmed cell death protein-1 (anti-PD-1) monoclonal antibodies (mAbs) (89). The gene discussed is PDCD1; the disease is metastatic melanoma.